Experiments on adult Wistar rats showed that injection of β-amyloid(25–35) (2 µg) into Meynert basal nuclei caused long-term memory deficiency which was detected 24 days after this injection by the memory trace retrieval in conditioned passive avoidance reflex (CPAR). The effects of noopept, an original nootropic and neuroprotective dipeptide, on the severity of this cognitive deficiency were studied. Preventive (for 7 days before the injury) intraperitoneal injections of noopept in a dose of 0.5 mg/kg completely prevented mnestic disorders under conditions of this model. Noopept exhibited a significant normalizing effect, if the treatment was started 15 days after the injury, when neurodegenerative changes in the basal nuclei, cortex, and hippocampus were still acutely pronounced. The mechanisms of this effect of the drug are studied, including, in addition to the choline-positive effect, its multicomponent neuroprotective effect and stimulation of production of antibodies to β-amyloid(25–35). Noopept efficiency in many models of Alzheimer disease, its high bioavailability and low toxicity suggest this dipeptide for further studies as a potential agent for the treatment of this condition (initial and moderate phases).
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
L. P. Kovalenko, M. G. Miramedova, S. V. Alekseeva, et al., Eksp. Klin. Farmakol., 65, No. 2, 53–55 (2002).
R. U. Ostrovskaya, T. A. Gudasheva, T. A. Voronina, et al., Ibid., No. 5, 66–72.
R. U. Ostrovskaya, T. Kh. Mirzoev, F. A. Firova, et al., Ibid., 64, No. 2, 11–14 (2001).
K. S. Us, P. M. Klodt, V. S. Kudrin, et al., Neirokhimiya, 23, No. 2, 122–126 (2006).
J. Y. Ban, S. O. Cho, S. Y. Jeon, et al., Neurosc. Lett., 420, No. 2, 184–188 (2007).
J. V. Bukanova, E. I. Solntseva, and V. G. Skrebitsky, Int. J. Neuropsychopharmacol., 5, 229–237 (2002).
Q. S. Chen, B. L. Kagan, Y. Hirakura, et al., J. Neurosci. Res., 60, No. 1, 65–72 (2000).
L. Giovannelli, F. Casamenti, C. Scali, et al., Neuroscience, 66, No. 4, 781–792 (1995).
T. A. Gudasheva, T. A. Voronina, R. U. Ostrovskaya, et al., Eur. J. Med. Chem., 31, No. 2, 151–157 (1996).
T. Harkany, S. O'Mahony, J. P. Kelly, et al., Behav. Brain Res., 90, 133–145 (1998).
M. Q. Liao, Y. J. Tzeng, L. Y. Chang, et al., FEBS Lett., 581, No. 6, 1161–1165 (2007).
R. U. Ostrovskaya, M. A. Gruden, N. A. Bobkova, et al., J. Psychopharmacol., 21, 611–619 (2007).
A. Pealsman, C. Hoyo-Vadillo, S. B. Seredenin, et al., Int. J. Dev. Neurosci., 21, 117–124 (2003).
Z. I. Storozheva, A. T. Proshin, V. V. Sherstnev, et al., BMC Pharmacol., 8, No. 1–49 (2008).
Author information
Authors and Affiliations
Corresponding author
Additional information
__________
Translated from Byulleten' Eksperimental'noi Biologii i Meditsiny, Vol. 146, No. 7, pp. 84–88, July, 2008
Rights and permissions
About this article
Cite this article
Ostrovskaya, R.U., Belnik, A.P. & Storozheva, Z.I. Noopept efficiency in experimental Alzheimer disease (cognitive deficiency caused by β-amyloid25–35 injection into Meynert basal nuclei of rats). Bull Exp Biol Med 146, 77–80 (2008). https://doi.org/10.1007/s10517-008-0211-6
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10517-008-0211-6